Zum Anzeigen dieser Inhalte ist ein JoVE-Abonnement erforderlich. Melden Sie sich an oder starten Sie Ihre kostenlose Testversion.
Method Article
OSTSS leads to pooled inflammatory mediators in the tear film, causing symptoms like epiphora and discomfort. Here, we present a case where therapeutic nasolacrimal lavage every 2 months resolved epiphora and itchiness, suggesting its efficacy as a therapeutic intervention for OSTSS. Additionally, we report subjective improvements in symptoms in 3 additional patients.
Ocular surface toxic soup syndrome (OSTSS) is characterized by inadequate tear drainage through the nasolacrimal duct system, leading to the accumulation of inflammatory mediators in the tear film. This condition can result in toxic keratoconjunctivitis, with symptoms such as conjunctival hyperemia, itchiness, discomfort, and epiphora. Dilation and irrigation are common diagnostic procedures in both optometry and ophthalmology, used to assess nasolacrimal duct obstruction in cases of epiphora. This technique involves the injection of saline into the nasolacrimal duct system through the puncta, followed by the evaluation of reflux, which indicates obstruction. Although intended to be diagnostic, many patients report significant improvements in epiphora and ocular comfort after the procedure. In this paper, we present a case study in which a patient achieved complete resolution of epiphora and itchiness following therapeutic nasolacrimal lavage performed every 2 months. Subjective improvements in symptoms in 3 additional patients are also reported. We propose nasolacrimal lavage not only as a diagnostic tool but also as an effective therapeutic intervention for managing OSTSS.
Tear flow is essential for ocular surface homeostasis, maintained through interactions among the secretory and neurovascular systems, with the meibomian glands, lacrimal gland, goblet cells, conjunctiva, and their vascular and neural networks working together to sustain a stable tear film1,2. This balance relies on the dynamic interplay between tear production and drainage, which directly affects the overall tear turnover rate (TTR)3. A reduced TTR can exacerbate dry eye symptoms by leading to the accumulation of inflammatory mediators on the ocular surface, resulting in what we term Ocular Surface Toxic Soup Syndrome (OSTSS). Reduced TTR is suspected to contribute to dry eye, as symptomatic patients typically have lower tear turnover rates compared to asymptomatic controls4. Tear production and turnover rates likely influence the cytokine environment of the ocular surface, both by delivering cytokines through the tear fluid and by removing those accumulated on the ocular surface5. The dysfunction of the nasolacrimal system, which impairs tear drainage and absorption of tear fluid components, may contribute to the development of OSTSS by allowing inflammatory mediators to accumulate on the ocular surface, potentially triggering abnormal immune responses and exacerbating dry eye pathology6,7.
Punctal plugs have long been a cornerstone in managing dry eye disease associated with aqueous tear deficiency by blocking tear drainage to enhance tear retention on the ocular surface8,9. However, the effectiveness of punctal occlusion has been questioned recently10. Lacrimal irrigation, or nasolacrimal lavage, on the other hand, offers a potential alternative treatment to alleviate dry eye symptoms in cases of suspected OSTSS. In this report, we present a case in which nasolacrimal lavage provided significant relief for a patient with mixed etiologies, demonstrating its versatility as a treatment option.
Consent for nasolacrimal lavage is similar to consent for probe and irrigation, with the primary difference being that nasolacrimal lavage is an off-label, therapeutic treatment for keratoconjunctivitis sicca and allergic conjunctivitis, whereas probe and irrigation is considered a diagnostic procedure to determine the cause of epiphora. Patients must be informed of the off-label nature of this treatment.
The goal of nasolacrimal lavage is to improve tear drainage through the nasolacrimal system to promote tear turnover and clear the lacrimal sac. There are no direct alternatives that accomplish the same goal.
Nasolacrimal lavage carries minimal risk. When performed correctly, and in the absence of nasolacrimal duct obstruction, patients will experience saline drainage either into the back of the throat (with the head tilted back) or into the nose (with the head tilted forward). Mild irritation may occur around the puncta or at the punctal opening. Additionally, there is a slight risk of unintentional contact with the eyelid or globe from the blunt cannula.
When in the setting of epiphora and clinically appropriate, nasolacrimal lavage is a procedure generally covered by insurance under the description of probe and irrigation.
A 73-year-old Black woman presented with complaints of intermittent, yet severe, itchiness medially and mild grittiness in both eyes. The patient's ocular medications included cyclosporine 0.05%, twice daily in both eyes; preservative-free artificial tears as needed in both eyes; alcaftadine 0.25%, once daily in both eyes; and eyelid wipes once daily. She had previously used tobramycin 0.3% and dexamethasone 0.1% four times daily for 10 days, which provided effective symptom relief, but her symptoms recurred upon discontinuation. Her medical history was notable for bilateral keratoconjunctivitis, bilateral meibomian gland dysfunction, and squamous blepharitis of the upper and lower eyelids in both eyes. Ocular surgical history included barrier laser retinopexy in the right eye for a retinal tear, performed 7 months prior. Systemic medications included atorvastatin for hyperlipidemia and a daily inhalation of fluticasone furoate 200 µg/umeclidinium 62.5 µg/vilanterol 25 µg for chronic obstructive pulmonary disease (COPD).
On ocular surface examination, there was trace inferior corneal staining in both eyes, 1+ bulbar conjunctival injection in both eyes, 1+ papillary reaction of the palpebral conjunctiva in both lower eyelids, mild conjunctivochalasis, 1+ blepharitis of both upper eyelids, and 3+ meibomian gland dysfunction with thickened secretions. Mild lower eyelid laxity was also noted in both eyes. Schimer's I score was 17 mm in the right eye and 14 mm in the left eye.
The patient reported pruritus in the inner canthus of both eyes, where tears drain from the ocular surface into the nasolacrimal duct system through the puncta. Additionally, there was conjunctival injection at the nasal aspect of the bulbar conjunctiva, where tears accumulate before draining from the ocular surface. These findings are consistent with ocular surface tear dysfunction syndrome (OSTSS), which is associated with the accumulation of allergen particulates and inflammatory mediators. Given this, nasolacrimal lavage was performed at the lower puncta of both eyes as an off-label therapeutic intervention to facilitate proper tear drainage and reduce the buildup of allergens and inflammatory mediators in the inner canthus.
The study received approval from the Colorado Multiple Institutional Review Board, and all research conformed to the tenets of the Declaration of Helsinki.
1. Preparation of the sterile field
2. Patient instructions
3. Procedure
Figure 1: Cannula positioning. (A,B) Inserting the cannula into the vertical canaliculus of the lower punctum, then rotating the cannula into the horizontal canaliculus. Please click here to view a larger version of this figure.
4. Post-procedure examination
The patient (Patient 1) initially reported 100% improvement in nasal itchiness immediately following the procedure. At her 3-month follow-up, she reported remaining free of pruritus since the previous visit. Upon examination, bilateral inferior corneal staining, bulbar injection, and papilla had resolved. Four months later, the patient returned to the clinic with a recurrence of medial itchiness in both eyes. Her bilateral inferior corneal staining, bulbar injection, and papilla had reapp...
Nasolacrimal lavage is a procedure designed to irrigate the nasolacrimal duct system, analogous to the use of a sinus rinse for the nasal passages. We hypothesize that it may remove allergens and inflammatory biomarkers from the tear drainage system, which could otherwise backflow onto the ocular surface. Additionally, nasolacrimal lavage aims to enhance tear turnover by clearing mucus or dacryoliths that may obstruct tear drainage. In essence, nasolacrimal lavage serves as an inverse to the commonly performed procedure ...
The authors have nothing to disclose.
We would like to express their sincere gratitude to the patient discussed in this case, who has since passed away. Her passing is deeply felt by both her family and the clinic staff. Throughout her treatment, her sincere appreciation during each nasolacrimal lavage not only inspired us to continue this procedure with other patients but also encouraged the writing of this manuscript. We hope that this manuscript serves as a small tribute to her memory.
Name | Company | Catalog Number | Comments |
Blunt Fill Needle | BD | 305180 | 18 G |
Lacrimal cannula | BVI VisiTec | 585068 | 25 G x 1/2 inch |
Luer Lock Disposable Syringe | Medline | SYR105010 | 5 mL |
Nitrile Gloves (SensiCare Ice) | Medline | MD26803 | Nitrile Gloves |
Polylined Sterile Field | Busse | 697 | 18' x 26", fenestrated |
Saline bullets | Hudson RCI | 200-59 | 5 mL sterile |
Genehmigung beantragen, um den Text oder die Abbildungen dieses JoVE-Artikels zu verwenden
Genehmigung beantragenThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. Alle Rechte vorbehalten